all report title image
  • Published In : Jan 2023
  • Code : CMI5479
  • Pages : 339
  • Formats :
      Excel/PDF
  • Industry : Pharmaceutical

Osteoporosis is a medical condition in which the bones become brittle and fragile due to decreased bone mass and bone mineral density, leading to frequent fragility fractures. Worldwide, one in three women over the age of 50 is at risk of developing osteoporosis. It could be due to hormonal changes or a lack of calcium and vitamin D. Along with increased incidences of fractures in older, postmenopausal women, osteoporosis may often lead to mobility loss and perhaps morbidity and death. A major reason for developing this disease and the associated bone loss in women is estrogen deficiency. Other important risk factors are genetics, advanced age, being underweight, smoking, alcohol abuse, etc. Ample intake of protein, calcium, and vitamin D may help prevent postmenopausal osteoporosis without pharmacologic means. Doctors also suggest regular physical activity and avoiding smoking and alcohol consumption to lower the risk. For premenopausal women (women naturally approaching menopause) and those with low bone density and other risk factors, estrogen and drugs are recommended for improved bone density and strength.

Market Dynamics

Increasing inorganic growth activities such as agreements among market players is expected to drive the growth of the global postmenopausal osteoporosis market over the forecast period. For instance, on June 10, 2021, Theramex UK Ltd, a global specialty pharmaceutical company announced a license and supply agreement with Enzene Biosciences Limited, a Biotechnology company for the registration and commercialization of Denosumab, an antiresorptive treatment for osteoporosis.

Key features of the study:

  • This report provides an in-depth analysis of the global postmenopausal osteoporosis market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global postmenopausal osteoporosis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc., Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global postmenopausal osteoporosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global postmenopausal osteoporosis market

Detailed Segmentation:

  • Global Postmenopausal Osteoporosis Market, By Drug Class:
    • Bisphosphonates
    • Selective Estrogen Receptor Modulators (SERMs)
    • RANK Ligand Inhibitors
    • Anabolic Class
    • Calcium Metabolism Modifiers
    • Others (Calcitonin, Denosumab, among Others)
  • Global Postmenopausal Osteoporosis Market, By Route of Administration:
    • Oral
    • Intravenous Route
    • Subcutaneous
  • Global Postmenopausal Osteoporosis Market By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Postmenopausal Osteoporosis Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • F.Hoffmann-La Roche Ltd
    • Mylan N.V. (Viatris Inc.)
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals PLC
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Sun Pharmaceutical Industries Ltd
    • Ligand Pharmaceuticals Incorporated
    • Paras Biopharmaceuticals Finland Oy
    • Eli Lilly and Company
    • TRANSCENTA HOLDING
    • Amgen
    • Gedeon Richter Plc.
    • Enzene Biosciences
    • Samsung BioepisL Radius Health, Inc.
    • Alvotech
    • AryoGen Pharmed

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Route of Administration
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Attractiveness Analysis
      • Market Opportunities
    • Product Launches
    • Merger, Acquisition, Collaboration
    • Regulatory Guideline and Compliances
    • Key Developments
    • PEST Analysis
    • Technology Landscape
    • PORTER’s Analysis
    • Pricing Analysis (2021)
  4. Global Postmenopausal Osteoporosis Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Supply and Demand
  5. Global Postmenopausal Osteoporosis Market, By Drug Class, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Bisphosphonates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Selective Estrogen Receptor Modulators (SERMs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • RANK Ligand Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Anabolic Class
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Calcium Metabolism Modifiers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others (Calcitonin, Denosumab, among Others)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  6. Global Postmenopausal Osteoporosis Market, By Route of Administration, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Intravenous Route
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Subcutaneous
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  7. Global Postmenopausal Osteoporosis Market, By Distribution Channel, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segments Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  8. Global Postmenopausal Osteoporosis Market, By Region, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By  Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By  Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By  Distribution Channel, 2017 - 2030, (US$ Million
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By  Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By  Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By  Distribution Channel, 2017 - 2030, (US$ Million
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By  Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By  Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By  Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By  Distribution Channel, 2017 - 2030, (US$ Million
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By  Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By  Route of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By  Distribution Channel, 2017 - 2030, (US$ Million
      • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • Pfizer Inc. *
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • F. Hoffmann-La Roche Ltd
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Mylan N.V. (Viatris Inc.)
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Fresenius Kabi AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Hikma Pharmaceuticals PLC
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GlaxoSmithKline plc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sun Pharmaceutical Industries Ltd
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Ligand Pharmaceuticals Incorporated
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Paras Biopharmaceuticals Finland Oy
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Eli Lilly and Company
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • TRANSCENTA HOLDING
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Amgen
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Gedeon Richter Plc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Enzene Biosciences
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Samsung BioepisL Radius Health, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Alvotech
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AryoGen Pharmed
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  10. Section
    • Research Methodology
    • About Us

*Browse 58 market data tables and 53 figures on “Postmenopausal Osteoporosis Market” - Global forecast to 203.

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.